- Home
- PHM vs BIIB Comparison
PHM vs BIIB Comparison
Compare PHM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHM
- BIIB
- Stock Information
- Founded
- PHM 1950
- BIIB 1978
- Country
- PHM United States
- BIIB United States
- Employees
- PHM N/A
- BIIB N/A
- Industry
- PHM Homebuilding
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PHM Consumer Discretionary
- BIIB Health Care
- Exchange
- PHM Nasdaq
- BIIB Nasdaq
- Market Cap
- PHM 27.2B
- BIIB 25.1B
- IPO Year
- PHM N/A
- BIIB 1991
- Fundamental
- Price
- PHM $128.09
- BIIB $158.59
- Analyst Decision
- PHM Buy
- BIIB Buy
- Analyst Count
- PHM 16
- BIIB 25
- Target Price
- PHM $145.00
- BIIB $258.57
- AVG Volume (30 Days)
- PHM 1.6M
- BIIB 1.6M
- Earning Date
- PHM 01-28-2025
- BIIB 10-30-2024
- Dividend Yield
- PHM 0.62%
- BIIB N/A
- EPS Growth
- PHM 10.14
- BIIB 10.05
- EPS
- PHM 13.56
- BIIB 11.06
- Revenue
- PHM $17,318,808,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- PHM $11.29
- BIIB N/A
- Revenue Next Year
- PHM $4.29
- BIIB N/A
- P/E Ratio
- PHM $9.53
- BIIB $14.55
- Revenue Growth
- PHM 2.80
- BIIB N/A
- 52 Week Low
- PHM $92.00
- BIIB $153.62
- 52 Week High
- PHM $149.47
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- PHM 43.32
- BIIB 41.81
- Support Level
- PHM $128.78
- BIIB $159.12
- Resistance Level
- PHM $136.14
- BIIB $165.29
- Average True Range (ATR)
- PHM 2.94
- BIIB 3.25
- MACD
- PHM 0.17
- BIIB 1.25
- Stochastic Oscillator
- PHM 23.12
- BIIB 70.36
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes, and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.